Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

43.47 +0.72 (+1.68%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna Inc

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRNA
From The Rosen Law Firm PA
Via GlobeNewswire
MRNA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
$100 Invested In This Stock 5 Years Ago Would Be Worth $500 Today
Via Benzinga
The Stock Market Isn't Rocking This Month But The S&P 500 Is Headed For Its Best August In 3 Years
Kellanova and Fortinet are leading the S&P 500's August performance. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Moderna to Host Investor Event - R&D Day and Business Updates
Via ACCESSWIRE
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2
Via ACCESSWIRE
Moderna's Options: A Look at What the Big Money is Thinking
Via Benzinga
Europe Approves Moderna's RSV Vaccine For Adults 60 And Over
Moderna secures European Commission approval for its mRNA RSV vaccine, mRESVIA, to protect adults 60+ from RSV-related respiratory disease. The approval follows positive EMA CHMP opinion, based on... 
Via Benzinga
Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)
Via ACCESSWIRE
Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1
Via ACCESSWIRE
Nasdaq 100 Slumps 1.6% As Traders Turn Cautious Ahead Of Powell's Jackson Hole Address
The Nasdaq 100 fell 1.6% on Thursday as investors awaited Fed Chair Powell's Jackson Hole speech. Private sector data and tech stock declines added to bearish sentiment. 
Via Benzinga
Topics Economy
Exposures Interest Rates
FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot
The FDA granted emergency use authorization for updated mRNA COVID-19 vaccines targeting the Omicron KP.2 strain, including new formulas from Moderna and Pfizer/BioNTech. These vaccines, designed to... 
Via Benzinga
Exposures COVID-19 Product Safety
Stocks Move Lower As Rate Cut Enthusiasm Fades
The enthusiasm that followed the release of the Federal Reserve's meeting minutes is already fading. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, PDD Holdings, Extreme Networks, and Sprinklr and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MNRA STOCK NEWS: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Moderna, Inc. Class Action
From Robbins LLP
Via GlobeNewswire
S&P 500, Nasdaq 100 Snap 8-Day Winning Streak: What Triggered Wall Street's Setback On Tuesday?
S&P 500 ended Tuesday's session with slight declines, halting its best winning streak since May 2024. Here's the latest. 
Via Benzinga
Topics Stocks
Exposures US Equities
GeoVax Labs: Is This Micro-Cap Biotech Stock a Boom or a Bust?
GeoVax Labs has seen its shares rise enormously over the past few days after an announcement from the World Health Organization relevant to one of its drugs. 
Via MarketBeat
Exposures COVID-19
S&P 500, Nasdaq 100 Extend 8-Session Winning Streak As Wall Street Jitters 'Go Poof': Monday's Key Stock Movers
Via Benzinga
Topics Stocks
Exposures US Equities
Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
Its 12-month relative strength performance is impressive, but Novavax now faces resistance. 
Via Investor's Business Daily
Rosen Law Firm Urges Moderna, Inc. (NASDAQ: MRNA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
MODERNA, INC. (NASDAQ: MRNA) INVESTOR ALERT: Investors With Large Losses in Moderna, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak. 
Via Benzinga
Topics ETFs
Exposures COVID-19 Product Safety
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release. 
Via MarketBeat
Exposures COVID-19 Product Safety
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
A clinical-trial failure for Pfizer and BioNTech means Moderna is leading the race to develop a combo shot for the flu and COVID-19. 
Via The Motley Fool
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna and Sprinklr and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MRNA Shareholder Notice: Robbins LLP Reminds Investors of the Class Action Filed Against Moderna, Inc.
From Robbins LLP
Via Business Wire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRNA
From The Rosen Law Firm PA
Via GlobeNewswire
Pfizer, BioNTech's COVID-19/Flu Combo Vaccine Fails To Meet Key Goal In Late-Stage Study
Pfizer and BioNTech report Phase 3 results for their combined mRNA vaccine against influenza and COVID-19. The trial met one of two primary immunogenicity objectives. Adjustments are planned to improve... 
Via Benzinga
Exposures COVID-19
MRNA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.